Rocket Pharmaceuticals News

Rocket Pharmaceuticals on Track for Lowest Close Since September 2022 -- Data Talk

Dow JonesNov 20 11:48 ET

A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $55

Moomoo NewsNov 20 08:00 ET · Ratings

Rocket Pharmaceuticals Price Target Maintained With a $39.00/Share by Canaccord Genuity

Dow JonesNov 19 17:39 ET · Ratings

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

BenzingaNov 19 14:47 ET

Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment

TipRanksNov 19 10:55 ET · Ratings

Rocket Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow JonesNov 19 10:54 ET · Ratings

Express News | Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44

BenzingaNov 19 10:44 ET

Sector Update: Health Care Stocks Lean Lower Premarket Tuesday

MT NewswiresNov 19 09:17 ET

Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target

BenzingaNov 19 09:15 ET · Ratings

Sector Update: Health Care

MT NewswiresNov 19 08:59 ET

A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $37 to $52

Moomoo NewsNov 19 08:00 ET · Ratings

Rocket Pharmaceuticals' RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed

TipRanksNov 18 20:47 ET · Ratings

Rocket Pharmaceuticals to Resume Patient Enrollment in RP-L301 Gene Therapy Phase 2 Trial in 2025

MT NewswiresNov 18 17:47 ET

Rocket Pharmaceuticals Has Not Initiated Enrollment in Phase 2 RP-L301 Study

TipRanksNov 18 16:26 ET

Promising Advancements in Gene Therapy: Buy Recommendation for Rocket Pharmaceuticals

TipRanksNov 18 15:55 ET

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference

BusinesswireNov 18 11:00 ET

Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $51

Moomoo NewsNov 15 08:31 ET · Ratings

BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating

Moomoo NewsNov 12 09:31 ET · Ratings

Express News | Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $62 Price Target

BenzingaNov 11 16:50 ET

Scotiabank Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Raises Target Price to $51

Moomoo NewsNov 11 09:33 ET · Ratings